GLAND2022-07-012022-09-30GLAND2022-09-30GLAND2022-03-31GLAND2022-04-012022-09-30GLAND2022-07-012022-09-30in-bse-fin:OtherExpenses1MemberGLAND2022-07-012022-09-30in-bse-fin:OtherExpenses2MemberGLAND2022-04-012022-09-30in-bse-fin:OtherExpenses1MemberGLAND2022-04-012022-09-30in-bse-fin:OtherExpenses2MemberGLAND2022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1GLAND2022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares543245GLANDNOTLISTEDINE068V01023GLAND PHARMA LIMITEDEquity2022-04-012023-03-312022-10-262022-10-10INRMillionsHalf yearlySingle segmentPharmaceuticals2022-10-2614:30:002022-10-2615:30:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedStandalone10483090000656240000111393300005043670000379000001713400001011550000171700003667200001266280000791463000032247000000322470000080651000021890000828400000023963000000000239630000015800000241210000024121000000164690000114.5514.550014.5514.55000<div>
<p><span>1. In terms of
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
2015, this Statement of Unaudited Standalone Financial Results for the quarter
and half year ended September 30, 2022 ("Unaudited Standalone Financial
Results") of the Company has been reviewed by the Audit Committee and
approved by the Board of Directors at their meeting held on October 26, 2022,
and have been subject to a limited review by the statutory auditors of the
Company.</span></p>
<p><span>2. The Unaudited
Standalone Financial Results of the Company have been prepared in accordance
with the Indian Accounting Standards notified under Section 133 of the
Companies Act 2013, as amended read with relevant rules thereunder and in terms
of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
2015, as amended (the "Listing requirements").</span></p>
<p><span>3. The Code of
Social Security 2020 ('Code') relating to employee benefits during employment
and post-employment received Presidential assent in September 2020. The Code
has been published in the Gazette of India. However, the date on which the Code
will come into effect has not been notified and the final rules/interpretation
have not yet been issued. The Company will assess the impact of the Code when
it comes into effect and will record any related impact in the period in which
the Code becomes effective.</span></p>
<p><span>4. The Company
operates in one single reportable business segment-
"Pharmaceuticals".</span></p>
<p><span><span>Refer notes 5 to
8 from the signed results submitted to the stock exchanges.</span></span></p>
<div></div></div>2022-04-012022-09-30UnauditedStandalone190520700001400160000204522300008451790000853600004563000001991560000261700007158300002412680000141396900006312540000063125400001560910000607900001621700000046908400000000469084000014860000470570000047057000000164690000128.528.490028.528.49000Power and fuel320670000Other expenses945610000Power and fuel661220000Other expenses175146000015529940000125326000000223700001000000000081570000005250000000533157000009675700002320471000015539070000012049800000526700000027608450000260000095369000045881540000015454400006296605000000861707600001646900007633250000076497190000764971900003261000002307000055680000094337000000999050000560000069889500001304100007124960000925460000225720000398380000086745200000096735700008617076000021990000-36824000001022900000150230000000022752800000370730000071583000000000-94990000084393000000000-277200000-101269000052998500000001342320000039575300000000000013500008192200000007300000000000000000003564200000-1536340000-20050900000000002092100000011200000120000002166000000185230000213767000017510000215518000031118200005267000000Re-measurement (loss)/gain on employee defined benefit plans2110000021100000Re-measurement (loss)/gain on employee defined benefit plans19850000198500005300000499000000